Almiral, solution for injections 75 mg/3 ml, 10 ampoules — Made in Cyprus — Free Delivery

Indications.

The preparation, when administered, is intended for the treatment of:

• inflammatory and degenerative forms of rheumatism, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis, vertebral pain syndrome, non-articular rheumatism;
• acute attacks of gout
• renal and biliary colic;
• pain and swelling after injuries and operations;
• severe migraine attacks.

The preparation, when administered as an intravenous infusion, is intended for the treatment or prevention of postoperative pain.

Contraindications.

Hypersensitivity to the active substance, sodium metabisulphite or any other component of the preparation

History of bleeding or perforation of the gastrointestinal tract associated with previous treatment with non-steroidal anti-inflammatory preparations (NSAIDs);

Active peptic ulcer/bleeding or history of recurrent peptic ulcer/bleeding (two or more separate episodes of established ulcer or bleeding)

III trimester of pregnancy;

Like other NSAIDs, diclofenac is also contraindicated in patients in whom the use of ibuprofen, acetylsalicylic acid or other non-steroidal anti-inflammatory preparations provokes attacks of bronchial asthma, angioedema, urticaria or acute rhinitis;

Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis);

Liver failure

Renal failure (creatinine clearance <15 ml/min/1.73 m2)

Congestive heart failure (NYHA II-IV)

High risk of postoperative bleeding, blood clotting, hemostasis disorders, hematopoietic disorders or cerebrovascular bleeding;

Treatment of PERIO-OPERATIVE pain with coronary artery bypass grafting (or use of a heart-lung machine)

Ischemic heart disease in patients with angina pectoris, myocardial infarction

Cerebrovascular disease in patients who have had a stroke or have episodes of transient ischemic attacks.

Diseases of the peripheral arteries.

In this dosage form, the preparation is contraindicated in children.

Compound

active ingredient: diclofenac;

3 ml solution (1 ampoule) contains diclofenac sodium 75 mg

excipients: propylene glycol, benzyl alcohol, sodium formaldehyde sulfoxylates, sodium metabisulfite (E 223), sodium hydroxide, water for injection.

Method of application and dose.

The preparation should be used in the most effective doses for a short period of time, taking into account the goals of treatment in each individual patient.

adults

The preparation Almiral, solution for injection, do not use for more than 2 days. If necessary, treatment can be continued with diclofenac tablets or suppositories.

injection

In order to prevent damage to nerve or other tissues at the injection site, the following rules must be observed.

The dose is usually 75 mg (1 ampoule) per day, which should be administered by deep injection into the upper external sector of the gluteus maximus muscle. In severe cases (eg, colic), the daily dose can be increased to two injections of 75 mg, between which an interval of several hours should be observed (one injection in each buttock). Alternatively, the 75 mg solution for injection may be combined with other dosage forms of diclofenac (eg tablets or suppositories) up to a maximum total daily dose of 150 mg diclofenac sodium.

In the setting of a migraine attack, clinical experience is limited to cases with an initial use of 1 ampoule of 75 mg, the dose should be administered as soon as possible after the use of 100 mg suppositories on the same day (if necessary). The total daily dose should not exceed 175 mg on the first day.

There are no data available on the use of Almiral for the treatment of migraine attacks for more than one day.

Children.

Diclofenac in the dosage form of a solution for injection is contraindicated in children.